These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27365379)

  • 1. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
    Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
    Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
    Dagdemir A; Durif J; Ngollo M; Bignon YJ; Bernard-Gallon D
    Epigenomics; 2013 Feb; 5(1):51-63. PubMed ID: 23414320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
    Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
    Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
    Hatta M; Naganuma K; Kato K; Yamazaki J
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):269-73. PubMed ID: 26505792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
    Shi Y; Jia Y; Zhao W; Zhou L; Xie X; Tong Z
    Int J Mol Med; 2018 Jul; 42(1):435-442. PubMed ID: 29620153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
    Chiaradonna F; Barozzi I; Miccolo C; Bucci G; Palorini R; Fornasari L; Botrugno OA; Pruneri G; Masullo M; Passafaro A; Galimberti VE; Fantin VR; Richon VM; Pece S; Viale G; Di Fiore PP; Draetta G; Pelicci PG; Minucci S; Chiocca S
    Antioxid Redox Signal; 2015 Jul; 23(1):15-29. PubMed ID: 25897982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21
    Chatterjee B; Ghosh K; Kanade SR
    Biofactors; 2019 Sep; 45(5):818-829. PubMed ID: 31317586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
    Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
    Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
    To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
    J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.